PMID- 8797023
OWN - NLM
STAT- MEDLINE
DCOM- 19961204
LR  - 20131121
IS  - 0018-506X (Print)
IS  - 0018-506X (Linking)
VI  - 30
IP  - 2
DP  - 1996 Jun
TI  - Prior treatment with estrogen attenuates the effects of the 5-HT1A agonist, 
      8-OH-DPAT, on lordosis behavior.
PG  - 145-52
AB  - The effects of repeated treatment with estradiol benzoate to ovariectomized rats 
      on the lordosis-inhibiting action of the 5-HT1A agonist, 
      8-hydroxy-2(di-n-propylamino) tetralin (8-OH-DPAT), were examined. In the first 
      week of hormonal priming, when rats were injected with estradiol benzoate (2.5-50 
      micrograms) plus 500 micrograms progesterone, all groups were inhibited by 
      intraperitoneal (i.p.) treatment with 0.15 mg/kg 8-OH-DPAT. However, in the 
      second week of hormone treatment, the effects of 8-OH-DPAT on lordosis behavior 
      were dose-dependently attenuated by estradiol benzoate. Such attenuation was 
      present when animals were treated with estradiol benzoate on the day of 
      ovariectomy and when the first estradiol benzoate treatment was delayed for 2 
      weeks after ovariectomy. At least 3 days after the first injection with estradiol 
      benzoate were required before the inhibitory effects of i.p. treatment with 
      8-OH-DPAT were attenuated. Although the magnitude was reduced, higher doses of 
      8-OH-DPAT (0.4, 0.45, and 0.5 mg/kg) continued to inhibit lordosis behavior even 
      after the second hormonal priming. When 8-OH-DPAT was infused directly into the 
      ventromedial nucleus of the hypothalamus (VMN), the lordosis-inhibiting effects 
      of 8-OH-DPAT were reduced as soon as 2 days after the first estradiol benzoate 
      injection. These data are interpreted as evidence that (1) estradiol benzoate's 
      attenuation of the effects of 8-OH-DPAT on lordosis behavior is both dose and 
      time dependent; (2) 5-HT1A receptor action in the VMN is attenuated by the 
      hormone treatment; and (3) female gonadal hormones reduce the potency of the 
      5-HT1A agonist, 8-OH-DPAT, in inhibiting lordosis behavior.
FAU - Jackson, A
AU  - Jackson A
AD  - Department of Biology, Texas Woman's University, Denton 76204, USA.
FAU - Uphouse, L
AU  - Uphouse L
LA  - eng
GR  - GM08256/GM/NIGMS NIH HHS/United States
GR  - R01 HD28419/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Horm Behav
JT  - Hormones and behavior
JID - 0217764
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 4G7DS2Q64Y (Progesterone)
RN  - 4TI98Z838E (Estradiol)
RN  - 78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin)
RN  - 983-30-2 (estradiol-17 beta-benzoate)
SB  - IM
MH  - 8-Hydroxy-2-(di-n-propylamino)tetralin/*pharmacology
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Estradiol/*analogs & derivatives/pharmacology
MH  - Female
MH  - Injections, Intraperitoneal
MH  - Progesterone/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Serotonin/classification/*drug effects
MH  - Serotonin Receptor Agonists/*pharmacology
MH  - Sexual Behavior, Animal/*drug effects
EDAT- 1996/06/01 00:00
MHDA- 1996/06/01 00:01
CRDT- 1996/06/01 00:00
PHST- 1996/06/01 00:00 [pubmed]
PHST- 1996/06/01 00:01 [medline]
PHST- 1996/06/01 00:00 [entrez]
AID - S0018-506X(96)90018-5 [pii]
AID - 10.1006/hbeh.1996.0018 [doi]
PST - ppublish
SO  - Horm Behav. 1996 Jun;30(2):145-52. doi: 10.1006/hbeh.1996.0018.